Addressing the unmet need in lung cancer: The potential of immuno-oncology

Cancer Treatment Reviews

Volumn 41, Issue 6, 2015, Pages 465-475

  Scagliotti, G V ^a   Bironzo, P ^a   Vansteenkiste, J F ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

CTLA 4; Immune checkpoint blockade; Immunotherapy; NSCLC; PD 1; PD L1

Indexed keywords

AFATINIB; ALECTINIB; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BMS 936559; CARBOPLATIN; CERITINIB; CISPLATIN; CRIZOTINIB; DOCETAXEL; DURVALUMAB; ERLOTINIB; GEFITINIB; GEMCITABINE; IPILIMUMAB; MPDL 3280A; NAVELBINE; NINTEDANIB; NIVOLUMAB; PACLITAXEL; PEMBROLIZUMAB; PEMETREXED; PLACEBO; PLATINUM COMPLEX; PROGRAMMED DEATH 1 RECEPTOR; RAMUCIRUMAB; RILOTUMUMAB; TAXANE DERIVATIVE; TICILIMUMAB; UNINDEXED DRUG; BIOLOGICAL MARKER; CD274 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; PROGRAMMED DEATH 1 LIGAND 1;

CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; GENE AMPLIFICATION; GENE MUTATION; GENE REARRANGEMENT; GENE TARGETING; GENE TRANSLOCATION; HUMAN; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; QUALITY OF LIFE; REVIEW; TREATMENT PLANNING; TUMOR IMMUNOLOGY; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; IMMUNOLOGY; LUNG NEOPLASMS; MORTALITY;

ANTIGENS, CD274; BIOLOGICAL MARKERS; BIOMARKERS; CARCINOMA, NON-SMALL-CELL LUNG; CTLA-4 ANTIGEN; HUMANS; LUNG NEOPLASMS;

EID: 84937636023     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2015.04.001     Document Type: Review

References (124)

1. Spiro S.G., Gould M.K., Colice G.L., American College of Chest Physicians Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes: ACCP Evidenced-based Clinical Practice Guidelines (2nd edition). Chest 2007, 132(Suppl. 3). 149-60S.
2. Ettinger D.S., Akerley W., Borghaei H., Chang A.C., Cheney R.T., Chirieac L.R., et al. Non-small cell lung cancer. J Natl Compr Canc Netw 2012, 10(1):1236-1271.
3. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: non-small cell lung cancer. Version V4.2014. [accessed 10.09.14]. http://www.nccn.org.
4. Thomas A., Hassan R. Immunotherapies for non-small-cell lung cancer and mesothelioma. Lancet Oncol 2012, 13(7):e301-e310.
5. Younes R.N., Pereira J.R., Fares A.L., Gross J.L. Chemotherapy beyond first-line in stage IV metastatic non-small cell lung cancer. Rev Assoc Med Bras 2011, 57(6):686-691.
6. Reck M., Popat S., Reinmuth N., De Ruysscher D., Kerr K.M., Peters S., et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014, 25(Suppl. 3):iii27-iii39.
7. Ferlay J., Steliarova-Foucher E., Lortet-Tieulent J., Rosso S., Coebergh J.W., Comber H., et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013, 49(6):1374-1403.
8. Anon [no author listed]. The threat of lung cancer in European women. Lancet 2013;381(9867):600.
9. Langer C.J., Manola J., Bernardo P., Kugler J.W., Bonomi P., Cella D., et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 2002, 94(3):173-181.
10. Maione P., Rossi A., Sacco P.C., Bareschino M.A., Schettino C., Ferrara M.L., et al. Treating advanced non-small cell lung cancer in the elderly. Ther Adv Med Oncol 2010, 2(4):251-260.
11. Meoni G., Cecere F.L., Lucherini E., Di Costanzo F. Medical treatment of advanced non-small cell lung cancer in elderly patients: a review of the role of chemotherapy and targeted agents. J Geriatr Oncol 2013, 4(3):282-290.
12. Besse B., Adjei A., Baas P., Meldgaard P., Nicolson M., Paz-Ares L., et al. 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. Ann Oncol 2014, 25(8):1475-1484.
13. Lilenbaum R., Villaflor V.M., Langer C., O'Byrne K., O'Brien M., Ross H.J., et al. Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials. J Thorac Oncol 2009, 4(7):869-874.
14. Perez-Moreno P., Brambilla E., Thomas R., Soria J.C. Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities. Clin Cancer Res 2012, 18(9):2443-2451.
15. Ginsberg M.S., Grewal R.K., Heelan R.T. Lung cancer. Radiol Clin North Am 2007, 45(1):21-43.
16. Righi L., Graziano P., Fornari A., Rossi G., Barbareschi M., Cavazza A., et al. Immunohistochemical subtyping of non-small cell lung cancer not otherwise specified in fine-needle aspiration cytology: a retrospective study of 103 cases with surgical correlation. Cancer 2011, 117(15):3416-3423.
17. Fumarola C., Bonelli M.A., Petronini P.G., Alfieri R.R. Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer. Biochem Pharmacol 2014, 90(3):197-207.
18. Blakely C.M., Bivona T.G. Resiliency of lung cancers to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance. Cancer Discov 2012, 2(10):872-875.
19. Crinò L., Metro G. Therapeutic options targeting angiogenesis in nonsmall cell lung cancer. Eur Respir Rev 2014, 23(131):79-91.
20. Smith DL, Acquaviva J, Sequeira M, Jimenez JP, Zhang C, Sang J, et al. The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer. Target Oncol 2014 Aug 1 [Epub ahead of print].
21. Takano T., Fukui T., Ohe Y., Tsuta K., Yamamoto S., Nokihara H., et al. EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. J Clin Oncol 2008, 26(34):5589-5595.
22. Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014;27;370(13):1189-97.
23. Seto T., Kiura K., Nishio M., Nakagawa K., Maemondo M., Inoue A., et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol 2013, 14(7):590-598.
24. Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13(3):239-246.
25. Cappuzzo F., Ciuleanu T., Stelmakh L., Cicenas S., Szczésna A., Juhász E., et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010, 11(6):521-529.
26. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361(10):947-957.
27. Sequist L.V., Yang J.C., Yamamoto N., O'Byrne K., Hirsh V., Mok T., et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013, 31(27):3327-3334.
28. Shaw A.T., Kim D.W., Nakagawa K., Seto T., Crinó L., Ahn M.J., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013, 368(25):2385-2394.
29. Fukuoka M., Wu Y.L., Thongprasert S., Sunpaweravong P., Leong S.S., Sriuranpong V., et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011, 29(21):2866-2874.
30. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362(25):2380-2388.
31. Zhou C., Wu Y.L., Chen G., Feng J., Liu X.Q., Wang C., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011, 12(8):735-742.
32. Chen G., Feng J., Zhou C., Wu Y.L., Liu X.Q., Wang C., et al. Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC). Ann Oncol 2013, 24(6):1615-1622.
33. Wu Y.L., Chu D.T., Han B., Liu X., Zhang L., Zhou C., et al. Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China. Asia Pac J Clin Oncol 2012, 8(3):232-243.
34. Solomon B.J., Mok T., Kim D.W., Wu Y.L., Nakagawa K., Mekhail T., et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014, 371(23):2166-2177.
35. Kan Z., Jaiswal B.S., Stinson J., Janakiraman V., Bhatt D., Stern H.M., et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 2010, 466(7308):869-873.
36. D'Arcangelo M., D'Incecco A., Cappuzzo F. Rare mutations in non-small-cell lung cancer. Future Oncol 2013, 9(5):699-711.
37. US Food and Drug Administration. Ceritinib. Available at: [accessed September 2014]. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm395386.htm.
38. F. Hoffmann-La Roche Ltd. Media release 4 July 2014. Available at: [accessed December 2014]. http://www.roche.com/media/media_releases/med-cor-2014-07-04.htm.
39. Scagliotti G.V., Parikh P., Von Pawel J., Biesma B., Vansteenkiste J., Manegold C., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26(21):3543-3551.
40. Syrigos K.N., Vansteenkiste J., Parikh P., von Pawel J., Manegold C., Martins R.G., et al. Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer. Ann Oncol 2010, 21(3):556-561.
41. Ceppi P., Volante M., Saviozzi S., Rapa I., Novello S., Cambieri A., et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006, 107(7):1589-1596.
42. Ahn M.A., Sun J., Ahn J.S., Jung S., Park K. Cisplatin plus pemetrexed (CP) versus cisplatin plus gemcitabine (CG) according to thymidylate synthase expression in non-squamous NSCLC: a biomarker-stratified randomized phase II trial. Ann Oncol 2014, 25(4):v1-v41. [abstract LBA42PR].
43. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355(24):2542-2550.
44. Reck M., von Pawel J., Zatloukal P., et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009, 27(8):1227-1234.
45. Reck M., von Pawel J., Zatloukal P., Ramlau R., Gorbounova V., Hirsh V., et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010, 21(9):1804-1809.
46. Johnson D.H., Fehrenbacher L., Novotny W.F., Herbst R.S., Nemunaitis J.J., Jablons D.M., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004, 22(11):2184-2191.
47. Ciuleanu T., Brodowicz T., Zielinski C., Kim J.H., Krzakowski M., Laack E., et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009, 374(9699):1432-1440.
48. Paz-Ares L.G., de Marinis F., Dediu M., Thomas M., Pujol J.L., Bidoli P., et al. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 2013, 31(23):2895-2902.
49. Fidias P.M., Dakhil S.R., Lyss A.P., Loesch D.M., Waterhouse D.M., Bromund J.L., et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009, 27(4):591-598.
50. Soon Y.Y., Stockler M.R., Askie L.M., Boyer M.J. Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials. J Clin Oncol 2009, 27(20):3277-3283.
51. Behera M., Owonikoko T.K., Chen Z., Kono S.A., Khuri F.R., Belani C.P., et al. Single agent maintenance therapy for advanced stage non-small cell lung cancer: a meta-analysis. Lung Cancer 2012, 77(2):331-338.
52. Gerber D., Schiller J. Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea. J Clin Oncol 2013, 31(8):1009-1020.
53. Di Maio M., Chiodini P., Georgoulias V., Hatzidaki D., Takeda K., Wachters F.M., et al. Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2009, 27(11):1836-1843.
54. Shepherd F.A., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell-lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000, 18(10):2095-2103.
55. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22(9):1589-1597.
56. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353(2):123-132.
57. Lee J.K., Hahn S., Kim W., Suh J.K., Keam B., Kim T., et al. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harbouring wild-type epidermal growth factor receptor: a meta-analysis. JAMA 2014, 311(14):1430-1437.
58. Rolfo C., Raez L.E., Bronte G., Santos E.S., Papadimitriou K., Buffoni L., et al. BIBF 1120/nintedanib: a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer. Expert Opin Investig Drugs 2013, 22(8):1081-1088.
59. Reck M., Kaiser R., Mallemgaard A., Douillard J.Y., Orlov S., Krzakowski M., et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 2014, 15(2):143-155.
60. Boehringer Ingelheim GmbH. Press release 27 November 2014. Available at: [accessed December 2014]. http://www.boehringeringelheim.com/news/news_releases/press_releases/2014/27_november_2014_oncology.html.
61. U.S. Food and Drug Administration News Release. FDA expands approved use of Opdivo to treat lung cancer. 4 March 2015. Available at: [accessed March 2015]. http://www.fda.gov.uk/NewsEvents/Newsroom/PressAnnouncements/ucm436534.htm.
62. Perol M., Ciuleanu T.-E., Arrieta O., Prabhash K., Syrigos K.N., Göksel T., et al. REVEL: a randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy. J Clin Oncol 2014, 32(Suppl. 5). [abstract LBA8006^].
63. Girard N., Jacoulet P., Gainet M., Elleuch R., Pernet D., Depierre A., et al. Third-line chemotherapy in advanced non-small cell lung cancer: identifying the candidates for routine practice. J Thorac Oncol 2009, 4(12):1544-1549.
64. Scartozzi M., Mazzanti P., Giampieri R., Berardi R., Galizia E., Gasparini S., et al. Clinical predictive factors for advanced non-small cell lung cancer (NSCLC) patients receiving third-line therapy: selecting the unselectable?. Lung Cancer 2010, 68(3):433-437.
65. Massarelli E., Andre F., Liu D.D., Lee J.J., Wolf M., Fandi A., et al. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer 2003, 39(1):55-61.
66. Sequist L.V., Waltman B.A., Dias-Santagata D., Digumarthy S., Turke A.B., Fidias P., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011, 3(75):75ra26.
67. Gainor J.F., Shaw A.T. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol 2013, 31(31):3987-3996.
68. Vesely M.D., Kershaw M.H., Schreiber R.D., Smyth M.J. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011, 29:235-271.
69. Mellman I., Coukos G., Dranoff G. Cancer immunotherapy comes of age. Nature 2011, 480(7378):480-489.
70. Tartour E., Zitvogel L. Lung cancer: potential targets for immunotherapy. Lancet Respir Med 2013, 1(7):551-563.
71. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012, 12(4):252-264.
72. Jadus M.R., Natividad J., Mai A., Ouyang Y., Lambrecht N., Szabo S., et al. Lung cancer: a classic example of tumor escape and progression while providing opportunities for immunological intervention. Clin Dev Immunol 2012, 2012:160724.
73. Zielinski C., Knapp S., Mascaux C., Hirsch F. Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer. Ann Oncol 2013, 24(5):1170-1179.
74. Fife B.T., Bluestone J.A. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev 2008, 224:166-182.
75. Brahmer J.R. Harnessing the immune system for the treatment of non-small-cell lung cancer. J Clin Oncol 2013, 31(8):1021-1028.
76. Holt G.E., Podack E.R., Raez L.E. Immunotherapy as a strategy for the treatment of non-small-cell lung cancer. Therapy 2011, 8(1):43-54.
77. Shepherd F.A., Douillard J.Y., Blumenschein G.R. Immunotherapy for non-small-cell lung cancer: novel approaches to improve patient outcomes. J Thorac Oncol 2011, 6(10):1763-1773.
78. Lynch T.J., Bondarenko I., Luft A., Serwatowski P., Barlesi F., Chacko R., et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012, 30(17):2046-2054.
79. Zatloukal P., Heo D.S., Park K., Kang J., Butts C., Bradford D., et al. Randomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2009, 27(Suppl. 15). [abstract 8071].
80. Gettinger S.N., Horn L., Gandhi L., Spigel D.R., Antonia S.J., Rizvi N.A., et al. Long-term survival, clinical activity, and safety of nivolumab (anti-PD-1; BMS-936558, ONO-4538) in patients (pts) with advanced non-small cell lung cancer (NSCLC). Int J Radiat Oncol 2014, 90(5):S34.
81. Rizvi N.A., Shepherd F.A., Antonia S.J., Brahmer J.R., Chow L.Q., Goldman J., et al. First-line monotherapy with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced non-small cell lung cancer (NSCLC): safety, efficacy, and correlation of outcomes with PD-L1 status. Int J Radiat Oncol 2014, 90(5):S31.
82. Ramalingam S.S., Mazières J., Planchard D., Stinchcombe T.E., Dy G.K., Antonia S.J., et al. Phase II study of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced, refractory squamous non-small cell lung cancer. Int J Radiat Oncol 2014, 90(5):1266-1267.
83. Garon E.B., Gandhi L., Rizvi N., Hui R., Balmanoukian A.S., Patnaik A., et al. Antitumor activity of pembrolizumab (Pembro; MK-3475) and correlation with programmed death ligand 1 (PD-L1) expression in a pooled analysis of patients (pts) with advanced non-small cell lung carcinoma (NSCLC). Ann Oncol 2014, 25(Suppl. 5):v1-v41.
84. Soria J.-C., Gettinger S., Gordon M., Heist R.S., Horn L., Spigel D.R., et al. Biomarkers associated with clinical activity of PD-L1 blockade in non-small cell lung cancer (NSCLC) patients (pts) in a phase I study of MPDL3280A. Ann Oncol 2014, 25(Suppl. 4):iv426-iv470.
85. Brahmer J.R., Horn L., Gandhi L., Spigel D.R., Antonia S.J., Rizvi N.A., et al. Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): survival and clinical activity by subgroup analysis. J Clin Oncol 2014, 32(Suppl. 5). [abstract 8112^].
86. Antonia S.J., Gettinger S., Goldman J., Chow L.Q., Juergens R., Borghaei H., et al. Safety and efficacy of first-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in non-small cell lung cancer (NSCLC). Int J Radiat Oncol 2014, 90(5):S32.
87. Antonia S.J., Brahmer J.R., Gettinger S., Chow L.Q., Juergens R., Shepherd F.A., et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC). Int J Radiat Oncol 2014, 90(5):S2.
88. Rizvi N.A., Antonia S.J., Shepherd F.A., Chow L.Q., Goldman J., Shen Y., et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) maintenance as monotherapy or in combination with bevacizumab (BEV) for non-small cell lung cancer (NSCLC) previously treated with chemotherapy. Int J Radiat Oncol 2014, 90(5):S31.
89. Gettinger S., Chow L.Q., Borghaei H., Shen Y., Harbison C., Chen A.C., et al. Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced non-small cell lung cancer (NSCLC). Int J Radiat Oncol 2014, 90(5):S34.
90. Phan G.Q., Yang J.C., Sherry R.M., Hwu P., Topalian S.L., Schwartzentruber D.J., et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003, 100(14):8372-8377.
91. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363(8):711-723.
92. Robert C., Thomas L., Bondarenko I., O'Day S., Weber J., Garbe C., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364(26):2517-2526.
93. Wolchok J.D., Hoos A., O'Day S., Weber J.S., Hamid O., Lebbé C., et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009, 15(23):7412-7420.
94. Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer 1981, 47(1):207-214.
95. Planchard D., Chaput-Gras N., Barlesi F., Mazieres J., Byrne N., Vuillier D., et al. Phase I study of tremelimumab (Trem) in combination with gefitinib (Gef) in epidermal growth factor receptor mutant (EGFR-mut) non-small cell lung cancer (NSCLC). Ann Oncol 2014, 25(Suppl. 4):iv426-iv470.
96. Scherpereel A., Cornelissen R., Di Pietro A., Kindler H.L., Nackaerts K., Antonia S.J., et al. Randomized, double-blind, placebo-controlled study of tremelimumab for second-line and third-line treatment of unresectable pleural or peritoneal mesothelioma. Ann Oncol 2014, 25(Suppl. 4):iv361-iv372.
97. Topalian S.L., Drake C.G., Pardoll D.M. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012, 24(2):207-212.
98. Jin H.T., Ahmed R., Okazaki T. Role of PD-1 in regulating T-cell immunity. Curr Top Microbiol Immunol 2011, 350:17-37.
99. Zhang Y., Huang S., Gong D., Qin Y., Shen Q. Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer. Cell Mol Immunol 2010, 7(5):389-395.
100. Korman A.J., Peggs K.S., Allison J.P. Checkpoint blockade in cancer immunotherapy. Adv Immunol 2006, 90:297-339.
101. Butte M.J., Keir M.E., Phamduy T.B., Sharpe A.H., Freeman G.J. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007, 27(1):111-122.
102. Zou W., Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008, 8(6):467-477.
103. Weber J. Immune checkpoint proteins: a new therapeutic paradigm for cancer-preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol 2010, 37(5):430-439.
104. Hellmann M.D., Creelan B.C., Woo K., Sima C.S., Iams W.T., Antonia S.J., et al. Smoking history and response to nivolumab in patients with advanced NSCLCs. Ann Oncol 2014, 25(Suppl. 4):iv426-iv470.
105. OPDIVO (nivolumab) US Prescribing Information. Available at: [accessed March 2015]. http://www.accessdata.fda.gov.uk/drugsatfda_docs/label/2015/125527s000lbl.pdf.
106. Carbone D.P., Socinski M.A., Chen A.C., Bhagavatheeswaran P., Reck M., Paz-Ares L. A phase III, randomized, open-label trial of nivolumab (anti-PD-1; BMS-936558, ONO-4538) versus investigator's choice chemotherapy (ICC) as first-line therapy for stage IV or recurrent PD-L1+ non-small cell lung cancer (NSCLC). J Clin Oncol 2014, 32(Suppl. 5). [abstract TPS8128].
107. Balmanoukian A.S., Rizvi N.A., Garon E.B., Patnaik A., Gandhi L., Leighl N.B., et al. Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC). Int J Radiat Biol 2014, 90(5):S1-S2.
108. Horn L., Herbst R., Spiegel D. An analysis of the relationship of clinical activity to baseline EGFR status, PD-L1 expression and prior treatment history in patients with non-small cell lung caners (NSCLC) following PD-L1 blockade with MPD-L3280A (anti-PDL1). J Thorac Oncol 2013, 8(Suppl. 2). [abstract MO18.01].
109. Herbst R.S., Gordon M.S., Fine G.D., Sosman J.A., Soria J.-C., Hamid O., et al. A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. J Clin Oncol 2013, 31(Suppl.). [abstract 3000].
110. Rizvi N.A., Chow L.Q.M., Dirix L.Y., Gettinger S.N., Gordon M.S., Kabbinavar F.F., et al. Clinical trials of MPDL3280A (anti-PDL1) in patients (pts) with non-small cell lung cancer (NSCLC). J Clin Oncol 2014, 32(Suppl. 5). [abstract TPS8123].
111. Wolchok J.D., Kluger H.M., Callahan M.K., Postow M.A., Gordon R.A., Segal N.H., et al. Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL). J Clin Oncol 2013, 31(Suppl.). [abstract 9012^].
112. Wolchok J.D., Kluger H., Callahan M.K., Postow M.A., Rizvi N.A., Lesokhin A.M., et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013, 369(2):122-133.
113. Antonia S.J., Goldberg S., Balmanoukian A., Narwal R., Robbins P.B., D'Angelo G., et al. A phase I open-label study to evaluate the safety and tolerability of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in combination with tremelimumab in patients with advanced non-small cell lung cancer (NSCLC). Ann Oncol 2014, 25(Suppl. 4):iv426-iv470.
114. Kanda S., Goto K., Shiraishi H., Kubo E., Tanaka A., Utsumi H., et al. Phase I study of anti-PD-1 antibody ONO-4538 (nivolumab) and chemotherapy in patients with advanced non-small-cell lung cancer. Ann Oncol 2014, 25(Suppl. 4):iv426-iv470.
115. Akbay E.A., Koyama S., Carretero J., Altabef A., Tchaicha J.H., Christensen C.L., et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 2013, 3(12):1355-1363.
116. Ribas A., Camacho L.H., Lopez-Berestein G., Pavlov D., Bulanhagui C.A., Millham R., et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 2005, 23(35):8968-8977.
117. Shimizu K., Nakata M., Hirami Y., Yukawa T., Maeda A., Tanemoto K., et al. Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Clin Oncol 2010, 5(5):585-590.
118. Ulloa-Montoya F., Louahed J., Dizier B., Gruselle O., Spiessens B., Lehmann F., et al. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J Clin Oncol 2013, 31(19):2388-2396.
119. Hellman M.D., Creelan B.C., Woo K., Sima C.S., Iams W.T., Antonia S.J., et al. Smoking history and response to Nivolumab in patients with advanced NSCLC. J Clin Oncol 2014, 25(4):426-470.
120. McLaughlin J. OncoTherapy Network. Available at: [accessed March 2015]. http://www.oncotherapynetwork.com/lung-cancer-targets/pd-I1-predictive-biomarker-anti-pd-1anti-pd-I1-therapies-non-small-cell-lung-cancer.
121. Mahoney K.M., Atkins M.B. Prognostic and predictive markers for the new immunotherapies. Oncology 2014, 28(3):39-48.
122. Naidoo J., Page D.B., Wolchok J.D. Immune modulation for cancer therapy. Br J Cancer 2014, 111:2214-2219.
123. Brahmer J.R., Horn L., Gandhi L., Spigel D.R., Antonia S.J., Rizvi N.A., et al. Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): survival and clinical activity by subgroup analysis. J Clin Oncol 2014, 32(5s). [abstract 8112^].
124. Rizvi N., Chow L., Borghaei H., Shen Y., Harbison C., Alaparthy S., et al. Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC. J Clin Oncol 2014, 32(5s). [abstract 8022].